Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia

Burchenal J H, Murphy M L, Ellison R R: Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of acute leukemia and allied disease.Blood 8, 965 (1953).

Mauer A M: Therapy of acute lymphoblastic leukemia in childhood.Blood 56, 1 (1980).

Poplack D G, Balis F M, Zimm S: The pharmacology of orally administered chemotherapy: a reappraisal.Cancer 58, 473 (1986).

Elion G B, Callahan S, Nathan H, Bieber S, Rundles R, Hitchings G H: Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase.Biochem Pharmac 12, 85 (1963).

Zimm S, Collins J M, Riccardi R, O’Neil D, Narang P K, Chabner B, Poplack D B: Variable bioavailability of oral mercaptopurine.New Engl J Med 308, 1005 (1983a).

Lennard L, Keen D, Lilleyman J S: Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations.Clin Pharmac Ther 40, 287 (1986).

Vasell E S: Complex effects of diet on drug disposition.Clin Pharmac Ther 36, 285 (1984).

Pinkerton C R, Welshman S G, Glasgow J F, Bridges J M: Can food influence the absorption of methotrexate in children with acute lymphoblastic leukemia?Lancet ii, 944 (1980).

Kalow W: Genetics of drug transformation.Clin Biochem 19, 76 (1986).

van Loon J A, Weinshilboum R M: Human lymphocyte thiopurine methyltransferase pharmacogenetics: effects of fenotype on 6-mercaptopurine-induced inhibition of mitogen stimulation.J Pharmac exp Ther 242, 21 (1987).

Correira M A, Castagnoli N Jr: Pharmacokinetics: II. Drug biotransformation, in Katzung B G (ed):Basic and Clinical Pharmacology, 3rd edn, p. 36. Los Altos, CA, Lange (1987).

Sjöqvist F, Bertilsson L: Slow hydroxylation of tricyclic antidepressants — relationship to polymorphic drug oxidation.Prog clin Biol Res 214, 169 (1986).

Lafolie P, Hayder S, Bjork O, Åhström L, Liliemark J, Peterson C: Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma.Acta Paediatr scand 75, 797 (1986).

Lönnerholm G, Kreuger A, Lindström B, Ludvigsson J, Myrdal U: Plasma and erythrocytic concentrations of mercaptopurine after oral administration in children.Pediatr Hemat Oncol 33, 27 (1986).

Bauer L A, Gilbaldi M, Westal R E: Influence of pharmacokinetic diurnal variation on bioavailability estimates.Clin Pharmacokinet 9, 184 (1984).

Rivard G E, Infante-Rivard O, Hoyox O, Champagne J: Maintenance chemotherapy for childhood acute lymphoblastic leukemia: better in the evening.Lancet ii, 1264 (1985).

Langevin A M, Koren G, Soldin S J, Greenberg M: Pharmacokinetic case for giving 6-mercaptopurine maintenance doses at night.Lancet ii, 505 (1987).

Riccardi R, Balis F, Ferrasa P, Lasorella A, Poplack D, Mastrangelo R: Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.Pediatr Hemat Oncol 3, 319 (1986).

Burton N, Barnett M, Aherne G, Evans J, Douglas I, Lister T: The effect of food on the oral administration of 6-mercaptopurine.Cancer Chemother Pharmac 18, 90 (1986).

Lennard L, Maddocks J L: Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine in human red blood cells.J Pharmac 35, 15 (1983).

Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Tufveson G. Grefberg N: Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients.Int J Immunopharmac 8, 1 (1986).

Balis F M, Holcenberg J S, Zimm S, Tubergen D, Collins J M, Murphy R F, Gilchrist G S, Hammond D, Poplack D G: The effect of methotrexate on the bioavailability of oral 6-mercaptopurine.Clin Pharmac Ther 41, 384 (1987).

Bokkerink J P, de Abreu R, van Laarhoven J, Bakker M, Hulscher T W, Schretlen E, de Bruijn C: Increased bioavailability of phosphoribosyl pyrophosphate as the basis for enhanced 6-mercaptopurine incorporation by methotrexate, in cultured human lymphoblasts.Adv exp Med Biol 195 B, 195 (1984).

Tidd D M, Paterson A R P: A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine.Cancer Res 34, 738 (1974).

Zimm S, Johnson G E, Poplack D G: Modulation of thiopurine cytotoxicity by physiologic concentrations of hypoxanthine.Proc Am Ass Cancer Res 27, 297 (1986).

Loo T L, Luke J L, Sullivan M P, Frei E III: Clinical pharmacologic observations on 6-mercaptopurine and 6-methylthiopurine ribonucleoside.Clin Pharmac Ther 9, 180 (1968).

van Baal J M, van Leeuwen M B, Schouten T J, de Abreu R A: Sensitive high-performance liquid chromatografic determination of 6-mercaptopurine, 6-thioguanine, 6-mercaptopurine riboside and 6-thioguanoside in biological fluids.J Chromatogr 336, 422 (1984).

Lavi L E, Holcenberg J S: A rapid and sensitive high-performance liquid chromatografic assay for 6-mercaptopurine metabolites in red blood cells.Analyt Biochem 144, 514 (1985).

Elion G B: Biochemistry and pharmacology of purine analogues.Fedn Proc 26, 888 (1967).

King M E, Honeysett J M, Howell S B B: Regulation ofde novo purine synthesis in human bone marrow mononuclear cells by hypoxanthine.J clin Invest 72, 965 (1983).

Plageman P G W, Marz R, Wohlhueter R M, Graff J C, Zylka J M: Facilitated transport of 6-mercaptopurine and 6-thioguanine and non-mediated permeation of 8-azaguanine in Novikoff rat hepatoma ceils and relationship to intracellular phosphoribosylation.Biochem biophys Acta 647, 649 (1981).

Ravis W R, Wang J S, Feldmann S: Intestinal absorption and metabolism of 6-mercaptopurine in the rat small intestine.Biochem Pharmac 83, 443 (1984).

Rees O A, Lennard L, Lilleyman J S, Maddocks J L: Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukemia.Cancer Chemother Pharmac 12, 87 (1984).

Zimm S, Collins J M, O’Neil D, Chabner B A, Poplack D G: Inhibition of first pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol.Clin Pharmac Ther 34, 810 (1983b).

Kong M C, Parks R E Jr: Incorporation of the purine moieties of guanosine and inosine analogs into nucleotide pools of human erythrocytes.Biochem Pharmac 24, 807 (1975).

Zimm S, Johnson G E, Chabner B A, Poplack D G: Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines.Cancer Res 45, 4156 (1985).

Lennard L, Lilleyman J S, Maddocks J L: The effect of folate supplements on 6-mercaptopurine remission maintenance therapy in childhood leukemia.Br J Cancer 53, 115 (1986).

Leleiko N S, Martin B A, Walsh M, Kazcow P, Rabinowitz S, Sterling K: Tissuespecific gene expression results from a purine and pyrimidinefree diet and 6-mercaptopurine in the rat small intestine and colon.Gastroenterology 93, 1014 (1987).

Hayder S, Lafolie P, Björk O, Åhström L, Peterson C: Pharmacokinetics and influence of food on oral 6-mercaptopurine in maintenance therapy in children with acute lymphoblastic leukemia.Proc Int Soc Paediatr Oncol,320 (1985).

Arndt C A, Balis F M, McCully C L, Jeffries S L, Doherty K, Murphy R, Poplack D G: Bioavailability of low-dose vs high-dose 6-mercaptopurine.Clin Pharmac Ther 43, 588 (1988).

Zimm S, Grygiel J J, Strong J M, Monks TJ, Poplack D G: Identification of 6-mercaptopurine riboside in patients receiving 6-mercaptopurine as a prolonged intravenous infusion.Biochem Pharmac 24, 4089 (1984).

Zimm S, Ettinger L J, Holcenberg J Set al. Phase 1 and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion.Cancer Res 45, 1869 (1985).

Sulh H, Koren G, Whalen C, Soldin S, Zipursky A, Greenberg M: Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia.Clin Pharmac Ther 40, 604 (1986).